Arca Biopharma | ABIO - Sales Revenues


Arca Biopharma reported 0 in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
Arca Biopharma 0 0 Mar/2025
Biogen USD 2.74B 490M Jun/2026
Brainstorm Cell Therapeutics 0 0 Mar/2025
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cipla INR 71.19B 5.78B Jun/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Cytokinetics USD 28.6M 9.25M Jun/2026
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Grifols EUR 2B 306.7M Mar/2026
Laboratory Of America USD 3.73B 190M Jun/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Otsuka Holdings JPY 702.05B 71.71B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026